Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2147484 | 0.85 | KMT2A (0.31) | CYP3A4KMT2AMEN1LMNACYP2C9 | |
| SCHEMBL19543529 | 0.82 | MAPK1 (0.37) | HSD17B10POLBGAACYP3A4KMT2A | |
| SCHEMBL23331736 | 0.82 | LMNA (0.31) | LMNA | |
| SCHEMBL1747681 | 0.81 | SMN1; SMN2 (0.39) | TSHRPOLBGAASMN1; SMN2KMT2A | |
| SCHEMBL15218253 | 0.81 | ALDH1A1 (0.38) | HSD17B10TSHRGAASMN1; SMN2RAB9A | |
| SCHEMBL3109277 | 0.81 | GLA (0.33) | SMN1; SMN2CYP3A4KMT2AMEN1LMNA | |
| SCHEMBL1764267 | 0.81 | MEN1 (0.38) | CYP3A4KMT2AMEN1LMNACYP2C9 | |
| SCHEMBL11989407 | 0.81 | ALDH1A1 (0.32) | HSD17B10TSHRMGLLALDH1A1 | |
| SCHEMBL29842557 | 0.81 | ALDH1A1 (0.32) | HSD17B10TSHRMGLLALDH1A1 | |
| SCHEMBL19543528 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
| EP-3466421-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | Osaka City University (JP) | 2019-04-10 | — | — | EP | disclosed |
| EP-2647386-B1 | LISSENCEPHALY THERAPEUTIC AGENT | UNIV OSAKA CITY (JP) | 2018-09-05 | — | — | EP | disclosed |
| US-9539298-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2017-01-10 | — | — | US | disclosed |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371359-B2 | Lissencephaly therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2016-06-21 | — | — | US | disclosed |
| EP-2947111-A1 | MONOFUNCTIONAL BRANCHED POLYETHYLENEGLYCOL AND BIO-RELATED SUBSTANCE MODIFIED BY SAME | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2015-11-25 | — | — | EP | disclosed |
| EP-2647386-A1 | LISSENCEPHALY THERAPEUTIC AGENT | Osaka City University (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | OSAKA CITY UNIVERSITY | 2013-09-19 | — | — | US | disclosed |
| US-7491705-B2 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244945-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, ERH | HSD17B10 923/4885TSHR 3475/4885POLB 2253/4885 |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | HSD17B10 573/4885TSHR 992/4885POLB 593/4885 |
| US-20070004643-A1 | Alpha-ketoamide derivative, and production method and use thereof | CAPN1, CAPN2, CAPNS1 | HSD17B10 585/4885TSHR 4084/4885POLB 1408/4885 |
| US-20160250276-A1 | LISSENCEPHALY THERAPEUTIC AGENT | ASPH, DCX, P4HA1 | HSD17B10 859/4885TSHR 3604/4885POLB 2252/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | HSD17B10 573/4885TSHR 992/4885POLB 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.